{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:43:13Z","timestamp":1789015393729,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"DOI":"10.1093\/jac\/dkm263","type":"journal-article","created":{"date-parts":[[2007,7,14]],"date-time":"2007-07-14T00:23:16Z","timestamp":1184372596000},"page":"681-684","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacokinetics of dalbavancin in plasma and skin blister fluid"],"prefix":"10.1093","volume":"60","author":[{"given":"David P.","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Seltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Buckwalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,7,12]]},"reference":[{"key":"key\n\t\t\t\t20171010171313_DKM263C1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1073\/pnas.53.4.881","article-title":"Lipid-phosphoacetylmuramyl-pentapeptide and lipid-phosphodisaccharide-pentapeptide: presumed membrane transport intermediates in cell wall synthesis","volume":"53","author":"Anderson","year":"1965","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171010171313_DKM263C2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2005.03.004","article-title":"Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens","volume":"53","author":"Streit","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171010171313_DKM263C3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397 a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010171313_DKM263C4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010171313_DKM263C5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity spectrum against over 6000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171010171313_DKM263C6","article-title":"The pharmacokinetics and renal excretion of dalbavancin in healthy subjects","volume-title":"Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002","author":"Dowell"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171010171313_DKM263C7","first-page":"291","article-title":"Attributes of dalbavancin: well distributed and completely eliminated","volume":"9","author":"Stogniew","year":"2003","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171010171313_DKM263C8","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171010171313_DKM263C9","doi-asserted-by":"crossref","first-page":"ii31","DOI":"10.1093\/jac\/dki006","article-title":"Pharmacokinetics and excretion of dalbavancin in the rat","volume":"55","author":"Cavaleri","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010171313_DKM263C10","unstructured":"Federal Food Drug Administration Uncomplicated and Complicated Skin and Skin Structure Infections\u2014Developing Antimicrobial Drugs for Treatment. Guidance for Industry Draft Guidance. July, 1998. http:\/\/www.fda.gov\/cder\/guidance\/index.htm (12 December 2005, date last accessed)"},{"key":"key\n\t\t\t\t20171010171313_DKM263C11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-8579(03)00084-0","article-title":"Production and resolution of cantharidin-induced inflammatory blisters","volume":"22","author":"Maglio","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171010171313_DKM263C12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171010171313_DKM263C13","article-title":"In vivo pharmacodynamic characterization of dalbavancin (DAL) in the murine thigh infection model","volume-title":"Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004","author":"Andes"},{"key":"key\n\t\t\t\t20171010171313_DKM263C14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1128\/AAC.50.2.788-790.2006","article-title":"Tissue penetration of telavancin after intravenous administration in healthy subjects","volume":"50","author":"Sun","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171010171313_DKM263C15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","article-title":"Pharmacokinetics of oritavancin in plasma skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose","volume":"49","author":"Fetterly","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171010171313_DKM263C16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/60\/3\/681\/2196910\/dkm263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T01:14:08Z","timestamp":1556673248000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/60\/3\/681\/736260\/Pharmacokinetics-of-dalbavancin-in-plasma-and-skin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,12]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2007,7,12]]},"published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm263","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,9]]},"published":{"date-parts":[[2007,7,12]]}}}